摘要
目的探讨普罗布考对早期糖尿病肾病患者血清脂联素和骨形态发生蛋白-7(BMP-7)的影响。方法 96例早期糖尿病肾病患者随机分为两组,治疗组50例,对照组46例;对照组采用常规治疗,治疗组在常规治疗的基础上加用普罗布考,治疗前后测定两组患者的微量白蛋白排泄率、血清脂联素和BMP-7。结果治疗组治疗前后分别为(157.6±42.8)μg/min、(72.6±20.4)μg/min,对照组治疗前后分别为(149.8±39.7)μg/min、(113.6±20.7)μg/min;两组治疗后均有明显改善,并且治疗组治疗后优于对照组(P<0.05);两组治疗后血清脂联素均明显降低,并且治疗组降低更明显(P<0.05);两组治疗后BMP-7均有明显升高,治疗组升高程度更明显(P<0.05)。结论普罗布考可以通过改善早期糖尿病肾病脂联素和BMP-7的表达,从而减少患者尿微量白蛋白排泄率。
Objective To study the effectiveness of probucol on the serum adiponectin and bone morphogenetic protein-7 （ BMP- 7 ） in patients with early diabetic nephropathy （DN）. Methods Ninety-six patients with early DN were randomly divided into two groups, the control group （n = 46 cases ） and the treatment group （n = 50 cases）. The patients of the control group were treated with the conventional treatment ; while the patients of the treatment group were treated with additional probucol based on the con- trol group. The course of therapy was eight weeks. The urinary albumin excretion rate （ UAER ） , serum adiponectin and BMP-7 were detected before and after the treatment. Results The UAERs in the control group was （ 149.8 ± 39.7 ） μg/min before the treatment and（ 113.6 ± 20.7 ） μg/min after the treatment. The UAERs in the treatment was （ 157.6 ± 42.8 ） μg/min before treat- ment and（72.6 ＋ 20.4 ）μg/min after the treatment. Adiponectin and BMP-7 were improved after treatment, while those of the treatment group were more significantly improved as compared to those of the control group （ P 〈 0.05 ）. Conclusion Probucol can improve the conditions of early DN through imDrovin~ the serum adiDonectin and BMP-7.
出处
《中华全科医学》
2012年第11期1706-1708,共3页
Chinese Journal of General Practice
